EuroIntervention PCRonline - Connecting with the community

Clinical research

Twelve month clinical and angiographic outcome after stenting of unprotected left main coronary artery stenosis with paclitaxel-eluting stents – results of the multicentre FRIEND registry

1. Cardiology Department, Rangueil Hospital, Toulouse, France; 2. Cardiology Department, Charles Nicolle Hospital, Rouen, France; 3. Cardiology Department, Jacques Cartier Institut, Massy, France; 4. Cardiology Department, Parc Clinic, Marseille, France; 5. Cardiology Department, Lavalette Clinic, Montpellier, France; 6. Cardiology Department, “Les Franciscaines” Hospital, Nimes, France; 7. Cardiology Department, Nantaises New Clinics, Nantes, France; 8. Cardiology Department, Pasteur Clinic, Toulouse, France; 9. Cardiology Department, Cardio Pneumo Center, Rennes, France; 10. Cardiology Department, Cardiology Department, Cavale Blanche Hospital, Brest, France; 11. Cardiology Department, Saint-Gatien, Tours, France; 12. Cardiology Department, North Cardiologic Center, Saint-Denis, France

Aims: To evaluate the angiographic and clinical outcome of patients undergoing paclitaxel-eluting stent (PES) implantation for unprotected left main coronary artery (ULMCA) stenosis in a multicentre, prospective registry. The overall event rate for PCI of ULMCA disease remains higher than in on-label use making additional outcome data and risk-stratification tools for the ULMCA population desirable.

Methods and results: A prospective registry included all patients with a significant (>50%) stenosis in ULMCA disease. In 151 of these patients the target lesion involved the distal bifurcation in 100 patients (66%), which was treated by predominantly using a “provisional T stenting” strategy.

In distal ULMCA disease group, 72% had only one stent implantation while 28% had multiple (either 2 or 3) stents implanted. At a median follow-up of 472±75 days, cardiac death occurred in 3 patients (2%) and major adverse cardiac and cerebrovascular events (MACCE) in 16 patients (10.6%).

Conclusions: In the drug-eluting stent era, paclitaxel eluting stent implantation of ULMCA stenosis provided excellent immediate and mid-term results in this selected population, suggesting that it may be considered as a safe and effective alternative to CABG for selected patients with ULMCA who are treated in institutions performing large numbers of PCI procedures.

– OR –